SEARCH

SEARCH BY CITATION

A new study shows off-label use of the drug alemtuzumab resulted in comparable outcomes compared to other induction therapies. We examine the factors weighing on the economy of this off-label strategy. Also this month, we take a look at the Nevada Donor Network's recent designation as a UPTN/UNOS “Member Not in Good Standing.”